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ABSTRACT 
The white adipose tissue (WAT) regulates energy homeostasis by storing and releasing 
energy in the form of fat as well as functioning as an endocrine organ secreting a myriad of 
different peptides. The heterogeneous WAT consists of various cell types including the lipid-
storing cells termed adipocytes. The energy-storing capacity of WAT is challenged by the 
rapid worldwide changes in diet and physical activity. This thesis aimed to identify novel 
factors regulating adipocyte function and to assess their impact on metabolic health.  
The transcription factor Early B Cell Factor 1 (EBF1) has previously been shown to regulate 
WAT morphology (adipocyte size and number). Low expression/activity is associated with 
WAT hypertrophy (few but large adipocytes), a metabolically detrimental phenotype. Study 
I aimed to determine if the expression and activity of EBF1 associated with metabolic risk 
markers. Results suggested that EBF1 expression and activity associated with parameters of 
the metabolic syndrome. 
Adipocytes in WAT is continuously renewed however, the turnover is irreversibly increased 
when a person gains weight. In fact, fat cell number is increased during weight gain and kept 
constant after weight loss. Study II aimed to identify the factor/s contributing to the 
maintenance of the high adipocyte number. Prospective analyses in clinical cohorts identified 
a set of growth factors that were highly expressed in obese compared to never-obese and 
were kept high after weight loss. Among these, transforming growth factor beta 3 (TGFB3) 
induced immature adipocyte proliferation. The WAT was studied in a mouse model 
expressing half of the gene expression and the results displayed a reduced proliferative 
capacity of immature adipocytes, hypertrophic WAT and glucose intolerance. 
The hypertrophic WAT is characterized by changes in several biological processes including 
inflammation. The chronic low grade inflammation in obesity is one of the processes believed 
to cause insulin resistance and type 2 diabetes mellitus. Study III focused on identifying 
upstream regulators of adipocyte inflammation. This led to the identification of SLC19A1, a 
gene encoding a cell membrane bound folate transporter. Folate is metabolized by the one-
carbon-cycle, an important pathway for DNA-methylation. We linked the inflammatory 
effects of reduced SLC19A1 expression to increased global DNA-methylation. In particular, 
methylation of a glucocorticoid receptor binding site in the promotor of the pro-inflammatory 
gene CCL2 regulated its expression. 
Altogether, this work contributes to the characterization of a dysfunctional WAT. 
Furthermore, the clinical relevance of the reported regulators of WAT function was 
evaluated. This knowledge confirms an emerging theory, that an important link between 
obesity and metabolic disease is limited WAT expansion. Therapies resolving WAT 
expansion exists and this knowledge could contribute in making these more effective. 
However, whether such therapies should replace interventions targeting behavior (nutrition 
and physical activity) warrants ethical appraisal and discussion.   
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1 BACKGROUND 
1.1 OBESITY 
The relevance of this thesis is signified by the obesity pandemic
1
. It has never been more vital 
to understand the mechanisms driving obesity and its subsequent co-morbidities including 
type 2 diabetes, cardio vascular disease and cancer
2
. 
Obesity is defined as BMI>30 kg/m
2
, i.e. a large body-weight in relation to the height. It is 
obvious that changes in the former variable drives the obesity pandemic. In the common 
population, the excess weight is constituted by fat stored in the WAT, which characterizes 
individuals with obesity. Why is obesity so prevalent today? Albert Einstein published the 
mass-energy equivalence formula 1905 which revealed the association between energy and 
mass. Hence, the chemical energy humans consume in form of food is stored in the WAT or 
converted to kinetic and thermal energy which manifest in body movement and heat, 
respectively. Today, it is common knowledge that body weight and fat mass can be reduced 
by eating less and moving more. Yet, understanding this concept has proven insufficient to 
reverse the increasing prevalence of obesity. In this section, I will discuss the origin of 
obesity, why it is a problem and how it can be prevented/treated. 
1.1.1 Evolutionary aspects of obesity 
A classical theory explaining the obesity pandemic has been the thrifty and/or the drifty 
genotype
3
. It suggests that the human body has evolved to store excess energy to survive 
times of famine (thrifty genotype) and/or the lack of exposure to predators (drifty genotype). 
Hence, human biology, which is viewed as static during the relatively short period of 
industrialization, is not suited to prosper in modern environments that promote an 
overbalance in energy
4
. Although genetics explain a fraction of the variations in BMI
5
, 
emerging knowledge suggest that the thrifty/drifty genotype theory is an oversimplification
6
.  
In fact, human biology is continuously evolving and maternal as well as paternal 
environments influence their own- and their offspring phenotype which is evident already in 
the F1 generation
7
. Hence, to understand the evolutionary aspects of obesity we must first 
appreciate the complexity of evolution.  
It is not controversial that the modern environment is a major contributor to the obesity 
pandemic by encouraging high caloric intake and sedentary behavior
8
. However, not 
everybody becomes obese in this environment. This spurs the inevitable “nature vs nurture” 
question; how much of the phenotype is hardwired in human nature and how much can be 
modified by the environment? In reality, all life forms are constantly adapting to their 
environments and the acquired adaptation can be transferred transgenerationally
6,7,9
.   The 
epigenome, defined as modifications of the chromatin that are not changes in the nucleotide 
sequence, function as a bridge between the environment and biological function, including 
human nature 
10–13
. For instance maternal and/or paternal diet pre-conception influence the 
body weight and WAT biology in the offspring
6,9
. Thus, the influence from human nature on 
a trait, such as obesity, cannot be separated from the environment and vice versa because both 
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are variables, and they are interwoven. Just to give an example of this interplay; an individual 
with a “thrifty genotype” is more likely to become obese but being obese also influence the 
environment of the person via exposures to stimuli such as social stress
14
 and reduced 
healthcare quality 
15
 which may contribute to drive the weight gain further
16
.   
Finally, phenotypic heterogeneity in body weight is observed in genetically identical 
organisms raised in the same environment suggesting that there is a stochastic aspect to 
obesity
17,18
. Thus, obesity may be acquired just by chance independent of the genes or 
environment. 
1.1.2 The link between obesity and disease 
Obesity is associated with a myriad of non-communicable diseases such as type 2 diabetes 
and cancer 
2,19–21
. Several processes have been linked to the pathophysiology of obesity 
including inflammation and ectopic lipid accumulation
22,23
. Both processes are associated 
with a hypertrophic WAT (few but large adipocytes in relation to fat mass)
24,25
. These 
observations in combination with observations linking WAT expandability and adipocyte size 
to metabolic disease
25–29
 indicate that obesity causes disease by exceeding the fat storage 
capacity. This theory suggests that the problem is not a large fat mass per se but rather the 
inability to further expand
30
. Hence, therapies treating obesity associated metabolic disease 
should aim at allowing further adipose tissue expansion via mechanisms such as 
adipogenesis
29
. This will be discussed in more detail in section 1.2.  
1.1.3 Treatment/prevention of obesity and its comorbidities 
As previously discussed, obesity becomes a problem when the body is not able to handle 
further energy supply. There are three solutions to the problem. The first is to reduce the 
energy supply which could be achieved by reducing food intake
31
. Several drugs has been 
used for this purpose but the most effective ones are the GLP-1 analogues
32
 which has several 
other positive antidiabetic effects as well. Another effective method to limit caloric intake is 
by changing the gastrointestinal anatomy via bariatric surgery
33
. A second therapeutic method 
is to increase energy expenditure
31
. Physical exercise and browning of adipose tissue are 
potential therapies that could be used to convert the chemical energy to movement and heat, 
respectively
24,34
. The third therapeutic target, which also is the most relevant to the work in 
this thesis, is to expand the storage capacity of the WAT to avoid ectopic lipid deposition and 
disease
19,24,29
. An effective way to do so is by activating the master regulator of adipocyte 
development (adipogenesis) PPARγ which has indeed been used as an antidiabetic therapy35. 
However, metabolic disease is not the only factor that reduces the quality of life in 
individuals with obesity. Excess body fat affects other features of life quality such as social 
acceptance
14–16
.  
The feasibility, cost effectiveness and the ethical consideration of these therapies warrants 
further discussion. In my opinion, the most reasonable strategy is to change the initial 
problem which is how modern societies are structured
8
. It is not at all necessary to live like 
hunter gatherers in order to reverse and prevent the increasing prevalence of obesity. In fact, 
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the oversupply of energy that accumulates and result in excess body fat over time could be 
prevented by walking as little as 2000 to 2500 extra steps per day
8
 or eating about 10-25 less 
kcal of energy per day
36
 which is equivalent to 1-2 cubes of sugar (~3-6g). Nevertheless, the 
WAT storage capacity needs to be enhanced if interventions aiming at behavioral changes are 
unsuccessful. Such strategies, in combination with elimination of the weight-stigma, could 
lead to a healthy obese world population. 
1.2 WHITE ADIPOSE TISSUE 
The WAT is the most plastic organ in the human body and a central regulator of energy 
homeostasis
24
. The tissue consists of several different cell-types including macrophages, T-
cells, fibroblasts, endothelial cells and adipocytes. The latter is characterized by its energy 
storing ability. The energy is stored as triglycerides in a lipid droplet. The adipocyte fraction 
comprises the majority of the WAT volume. Furthermore, the WAT is an endocrine organ 
that secretes a number of hormones that may act in para- and/or endocrine fashion. Many of 
the secreted peptides are pro-inflammatory cyto- and chemokines. In metabolically healthy 
individuals, the WAT regulate whole body homeostasis by buffering energy and secreting 
hormones (adipokines) that modulate functions in other organs. However, in an metabolically 
unhealthy state, often observed in individuals with obesity, these functions becomes 
dysfunctional and the WAT is instead characterized by inefficient expansion, inefficient lipid 
mobilization and a low grade chronic release of pro-inflammatory adipokines
24
. 
1.2.1 White adipose tissue expansion 
The plastic ability of the WAT is regulated by the energy balance in the body. Hyper-caloric 
conditions demand WAT expansion whereas hypo-caloric conditions induce the release of 
energy from WAT and thus, resulting in a reduction of its mass
24
. The expansion of WAT 
occurs via two processes, increased adipocyte size or increased adipocyte number
37
. The 
latter is constantly renewed with a 10% annual turnover-rate
37
. The inter-individual variation 
in the morphology for any given fat mass is large but on average, moving from low fat mass 
to higher is mainly associated with increased adipocyte size until a plateau of about 800 pL 
where the tissue starts to expand mainly via increased cell numbers
37
. A hyperplastic WAT 
(many small fat cells for a given fat mass) is associated with good metabolic health
24,26
 
probably because it is permissive for additional caloric over-supply. Several processes have 
been implicated in tissue expansion such as adipogenesis, angiogenesis, extracellular 
remodeling and inflammation
24,25,28,29
. In addition, proliferation of adipocyte progenitors 
(undifferentiated adipocytes) is also an important mechanism as the aforementioned 
processes are dependent of the availability of these cells. In contrast, weight loss is only 
associated with reduced fat cell size but no reduction in number, at least after rapid weight 
loss post bariatric surgery 
37,38
. This phenomenon would suggest that a post obese state is 
metabolically beneficial in relation to a never obese state at a given fat mass. In fact, this 
notion has recently been confirmed
38
. The underlying factors determining WAT adipocyte 
cellularity are poorly understood and warrant further investigation. Stimuli during gestation 
and early life has been proposed to be of vital importance
6
. Other mechanisms involve 
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specific transcription factor activity
39
 and disturbed circadian rhythms
40
. Increased 
understanding of the mechanisms regulating WAT expansion will allow us to develop 
strategies to maintain a high consumption of food combined with physical inactivity without 
disturbing metabolic health.     
1.2.2 White adipose tissue inflammation 
The intimate association between metabolism and the immune system is well established
41
 
and has set the foundation of a new term, namely immunometabolism 
42
. It is well known that 
obesity is associated with an inflammatory state and that the WAT contribute to the systemic 
inflammation
22,43–46
. The pro-inflammatory state in WAT during obesity has been known in 
about two and a half decades
47
 and its causal effect on insulin resistance is well 
studied
41,43,44,48
. Hence, it makes a lot of sense to treat metabolic disease by lowering 
inflammation. However, such treatments have not been successful
49
 suggesting that the 
inflammation may have beneficial functions in maintaining metabolic homeostasis. In fact, it 
has been suggested that chronic insulin exposure and insulin resistance in adipocytes 
precedes the inflammation
46,50
. One could speculate that the insulin resistance is a result of 
energy oversupply and that the subsequent inflammation is activated to remodel the WAT to 
make room for the surplus energy. This model is supported by findings suggesting that 
transient activation of inflammation is essential for the WAT to expand and the lack of 
inflammation results in lipodystrophy
51
. Furthermore, inflammation is believed to cause 
insulin resistance through induced lipid mobilization from the WAT to ectopic deposition
52
. 
This may be true however; lipid mobilization is needed in some instances such as during 
physical exercise. Inhibition of inflammation during physical exercise limits visceral fat 
loss
53
. Taken together, inflammation has long been considered as a metabolically detrimental 
process, a view that is being challenged with emerging reports. Hence, the interplay between 
metabolism and the immune system seem to be more dynamic and context-dependent than 
previously thought. Understanding this complexity could help find strategies to fine-tune it 
and restore immunometabolic homeostasis. 
1.3 FROM ENVIRONMENT TO PHENOTYPE: THE ROLE OF THE 
EPIGENOME AND THE TRANSCRIPTOME 
As discussed in section 1.1.1 of this thesis, biology cannot be viewed separate from its 
environment and they are not necessarily more or less plastic than each other. Charles 
Darwin’s theory of natural selection may have contributed to a static view of biology but 
today we know that individual organisms constantly adapt to their environments, a 
phenomenon termed phenotypic plasticity
54
. Environmental stimuli alter the structure of the 
chromatin itself which results in an altered gene expression
12
. The metabolism functions as a 
bridge between the environment and the epigenome which result in an altered gene 
expression
11,12
. We know of thousands of metabolites that can function as substrates or co-
substrates to regulate hundreds of epigenetic modification and/or other post translational 
modifications in the cell
13
 whereas the most well-studied is DNA-methylation. This 
knowledge has helped us understand that the nucleotide order of the DNA-molecule is 
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insignificant without an environment. Altogether, it is important to study epigenetics and 
gene expression in order to fully understand the mechanisms regulating WAT dysfunction. 
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2 AIMS 
2.1 GENERAL AIM 
The overarching aim was to identify novel regulators of adipocytes and link them to traits of 
the metabolic syndrome. This was achieved by starting with WAT biopsies from well-
phenotyped clinical cohorts and study associations between gene expression and various 
clinical measures or WAT phenotypes. Subsequent functional analyses of these factors were 
studied in vitro in various cell types and/or in vivo in a mouse model.  
2.2 SPECIFIC AIMS 
2.2.1 Study I 
The aim was to characterize the clinical relevance of EBF1, a transcription factor previously 
described to regulate adipogenesis and WAT morphology. 
2.2.2 Study II 
The primary aim was to identify regulators of the induced and irreversible adipocyte 
cellularity in WAT of obese individuals.  
2.2.3 Study III 
The aim was to study the regulation of DNA-methylation in adipocytes and its link to 
adipocyte function and insulin resistance in individuals suffering from obesity.  
  9 
3 METHODOLOGICAL CONSIDERATIONS 
3.1 HUMAN COHORTS 
All studies in this thesis include human cohorts. The study-individuals are grouped depending 
on the research question (such as comparisons between lean and obese or obese and post-
obese etc.). Characteristics of the WAT, including the transcriptome, is mapped and 
correlated with clinical characterization of the study-subjects.  
WAT biopsies are taken in the mornings after an overnight fast. This minimizes the influence 
of dietary and/or circadian factors on the results. However, the timing of the last meal and the 
misalignment between biological and astronomical circadian rhythms may still constitute as 
confounders
55
. In addition, differences between groups are context dependent and may be- or 
not be evident in certain settings such as in the presence of insulin
56
.  
The study-participants are mainly females and the data may not be extrapolated to males. It 
warrants particular consideration when studying WAT as there are remarkable differences in 
its expansion and distribution between genders
24,57
. Furthermore, the fat distribution is not 
taken into account when subdividing the BMI groups (i.e. lean, overweight or obese). Inter-
individual differences in body-weight are influenced by muscle mass. However, the study 
participants are not athletes or body builders thus; fat mass is the main variable explaining the 
variations in BMI. The total fat mass is less important than the body-fat distribution as a 
predictor of metabolic health
23,57
. The subdivision according to BMI was still used as it is 
common practice in the clinic. 
The transcriptome of WAT was compared between groups to identify new factors that may 
influence its function. The gene expression level ex vivo may not be a perfect representation 
of the state in vivo. The procedure in which the biopsy is taken may induce a stress response 
locally in the tissue as well as systemically if the individual experience fear/nervousness 
when being exposed to the needle. Extraction of the different cell fractions of the WAT 
requires collagenase treatment and centrifugation which most likely alter the transcriptome. A 
better representation of the WAT transcriptome/proteome may be assessed when novel 
techniques are developed and made available.    
3.2 CELL CULTURES 
Cell cultures were used in study I and II. Differentially expressed transcripts identified in the 
clinical cohorts were studied in vitro in primary human and murine WAT-derived cells or 
mouse embryonic fibroblasts. These systems allow us to study the cells in an isolated setting 
and manipulate gene expression or the micro-environment in the conditioned media. 
However, adipocytes crosstalk with other cell types to facilitate tissue function in vivo 
42,58
. 
Thus, some factors may not have effects in vitro but still be relevant for WAT function.  
As mentioned in chapter 1, WAT dysfunction is characterized by inter alia chronic 
inflammation, reduced adipogenic ability and increased basal lipolysis. Hence, these readouts 
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are commonly used in the in vitro system to characterize the role of a gene/protein on WAT 
function. The processes are subdivided into “good” and “bad” i.e. a gene that is highly 
expressed in a metabolically unhealthy state is expected to induce “bad” pathways and vice 
versa for the opposite. As discussed previously, these processes are dynamic and context-
dependent in vivo and the “good/bad” subdivision of tissue function may mislead and limit 
our understanding of biology.    
3.3 ANIMAL MODELS 
A transgenic mouse model was used in study II to test the causal role of Tgfb3 in vivo. It was 
of particular importance to use an animal model in this study as the data in vitro suggested 
that TGFB3 regulate progenitor proliferation. The effects on WAT cellularity is also 
dependent on adipogenesis and hence, induced proliferation may not necessarily translate into 
increased adipocyte cellularity.  
The way humans and mice store fat is different. Mice store fat mainly in the visceral depot 
and humans in the subcutanous
59
. The differences between depots, at least in mice, seem to 
be dependent of the microenvironment of the depot and not intrinsic in the cells
60
. Although 
mice are not equal to humans, they constitute a model organism that can be used to identify 
qualitative effects on WAT function. 
  
  11 
 
4 RESULTS AND DISCUSSION 
4.1 STUDY I 
In study I, we demonstrated that EBF1 levels and activity in WAT are associated with several 
measures of metabolic health. As EBF1 is a well-established regulator of WAT function 
(regulating adipogenesis, inflammation and lipolysis)
39,61,62
, these data support the notion that 
WAT function is relevant for overall metabolic health. The causal link between EBF1 
expression and adipose tissue function has been established prior to this study
39
 but they did 
not report the association to clinical parameters in humans. This study in combination with 
the previous studies on EBF1 function in WAT suggests that therapies aiming at targeting its 
transcriptional activity could be used to treat metabolic disease. 
How is EBF1 activity regulated and how can its activity be targeted? Specific ligands that 
activates EBF1 activity remain unknown however, inflammation (i.e. TNFα stimulation in 
vitro) reduce EBF1 expression in adipocytes
39
. This is not likely mediated via direct 
mechanisms as TNFα stimulation perturbs the characteristics of adipocytes, including high 
EBF1 expression. It is tempting to just imagine the DNA strand as a two-dimensional static 
molecule that EBF1 bind to, at specific motifs, after receiving a signal in form of a ligand or 
similar. Today we know that the chromatin is a three-dimensional structure and it is 
dynamic
63
. It can move specific regions of DNA into machineries of proteins involved in 
specific nuclear functions such as gene transcription. The three-dimensional chromatin 
structure is in large parts shaped by the cellular metabolic state via epigenetic mechanisms
11
. 
Thus, it is conceivable that EBF1 activity is regulated by specific metabolic states which 
shape the chromatin allowing EBF1-motifs to be accessible for gene transcription.  
In mice and humans EBF1 activity is associated with adipocyte cellularity independent of fat 
mass
39
 suggesting that interventions increasing EBF1 activity could increase adipocyte 
number without influencing total fat mass. However, in individuals with behavioral patterns 
resulting in a caloric oversupply, the WAT will continue to expand and a threshold for a 
hypertrophic phenotype will be reached at a larger fat mass. This suggests that potential 
therapies targeting EBF1 activity should be combined with intervention managing behavioral 
patterns. 
4.2 STUDY II 
Study II was performed to identify regulators of WAT adipocyte cellularity. A novel 
regulator of adipocyte cellularity, namely TGFB3 was identified. This factor is proposed to 
induce fat cell number in obesity by regulating pre-adipocyte proliferation. When obese 
individuals lose weight (termed post-obesity) TGFB3 expression is unaltered indicating that it 
contributes and explains part of the maintenance of elevated and irreversible adipocyte 
turnover once an individual becomes obese. Mice expressing half the mRNA levels compared 
to wild-type littermates displayed perturbed glucose metabolism when fed with a high fat diet 
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but not on a regular chow diet.  These findings support that WAT expandability is important 
for metabolic health. 
The factors inducing TGFB3 expression during weight gain remain unknown but it is 
possible that, as discussed above, the metabolic changes induce its expression via epigenetic 
mechanisms. Another explanation could be that the progenitor pool is induced during hyper-
caloric conditions and the accumulation of this cell type maintains a high TGFB3 expression 
in the WAT. Nevertheless, instead of understanding the mechanisms regulating its 
expression, recombinant TGFβ3 can be injected in patients. In fact, this has already been 
tested for anti-scarring therapies under the trademark Avotermin
64
. However, the timing of 
TGFβ3 injections in relation to adipogenic signals need to be investigated in order to expand 
the tissue efficiently as a chronic induction of progenitor proliferation may inhibit adipocyte 
differentiation.  
4.3 STUDY III 
A novel regulator of inflammation, namely SLC19A1, was identified and characterized in 
Study III. We observed that the expression of several genes involved in folate and methionine 
metabolism (one carbon cycle) was altered in WAT of individuals with obesity. SLC19A1 
expression displayed the strongest association to pro-inflammatory pathways. We linked the 
reduced expression of this gene to an induced global DNA-methylation. In particular, we 
showed that DNA-methylation in the promoter of the pro-inflammatory gene CCL2 induced 
its gene expression by modulating glucocorticoid receptor activity. These findings contribute 
to the understanding of the link between metabolism and adipocyte function. 
An important controversy of this study is that knockdown of SLC19A1 in vitro resulted in 
increased DNA methylation even though folate and the universal methyl donor S-
adenosylmethionine levels decreased. In fact, whole cellular metabolism is inter-woven and 
the one carbon cycle is not an isolated system
65
. In this study we reduced the expression of 
one gene encoding a folate transporter. The intracellular folate is connected to a myriad of 
metabolic pathways which involves several other intermediary metabolites as well as other 
enzymes and transporters
65
. Furthermore, S-adenosylmethionine and DNA methylation is just 
one out of hundreds of epigenetic modifications that may be influenced by the metabolome
13
. 
Understanding the complexity of such systems is made possible with omics tools and deeper 
understanding of these systems will probably be elucidated in the near future. 
This study suggest that folate metabolism is important for adipocyte function and metabolic 
health which is supported by a randomized control trial in humans
66
. However, folate alone is 
not likely enough to treat insulin resistance but it may constitute an ingredient in a mixture of 
metabolites. In fact, several metabolites are altered in individuals with obesity and metabolic 
disease
67
.  
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4.4 FUTURE PERSPECTIVE 
The studies in this thesis report three regulators of adipocyte function and metabolic health. 
Where do we go from here? Before moving on discussing future perspectives we need to 
define what the end goal is. The answer should be obvious; to reduce human suffering and 
improve the quality of life for humankind. If this is the goal, future research should focus on 
identifying therapies that can regulate WAT function. These interventions could involve 
treatment with drugs targeting specific mechanisms in adipocyte or behavioral interventions. 
The latter would require understanding of what behavioral patterns that causes an unhealthy 
WAT phenotype (hypertrophy and inflammation).  
The next step is to evaluate if therapies targeting WAT expansion and/or inflammation can be 
used to treat metabolic disease. If such therapies are successful, the impact on the subjective 
improvement in patient life-quality needs to be evaluated.  
5 CONCLUSION 
The structure of modern societies promotes an imbalance between energy intake and energy 
expenditure resulting in increased fat mass and obesity over time. This spurred scientists to 
map WAT function in health and disease in order to counteract obesity itself as well as its 
comorbidities. Collectively, decades of characterizations suggests that the problem with 
obesity is not that the WAT expands but rather that its expansion is limited and that once this 
limit is reached, individuals become metabolically sick. Chronic low grade inflammation is 
one characteristic of WAT that has reached its expansion. The work herein supports the 
existing theory and contributes to the understanding of the underlying mechanisms. The first 
two studies and the last study link metabolic health to tissue remodeling/expansion and 
inflammation, respectively. Taken together, this suggests that therapies to treat metabolic 
disease by mechanisms in WAT should aim at allowing it to further expand. The future will 
tell if humankind will solve the problem with obesity by modifying the fat storage capacity of 
the body, adjust the behavior to adapt to the environment or re-format the environment to 
adapt to the existing behavior.  
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“There are very few new things in this world, very few. That’s why people that are young, if 
they’re smart, try to profit from the experience of an older guy so they won’t have to go 
through all the pain and suffering. But a certain amount of pain and suffer is good, because it 
makes a person think they’ve learned.”  
– Cus D’Amato 
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